condition found
Features: |
Lycopene is a naturally occurring carotenoid found predominantly in tomatoes and other red fruits and vegetables. Antioxidant Properties: -Lycopene is a powerful antioxidant. It helps neutralize free radicals, which can reduce oxidative stress—a factor implicated in cancer development. Possible concern about interfering with chemotherapy and radiation therapy. However this review disagrees. Inflammation Reduction: -Some studies suggest that lycopene may help lower levels of inflammation, another process linked to cancer progression At supraphysiological or extremely high concentrations, lycopene may have the potential to switch from an antioxidant to a prooxidant role -The prooxidant effect of lycopene has been observed under conditions of high oxygen tension. In vitro studies have suggested that in environments with elevated oxygen levels, lycopene might promote rather than neutralize the production of reactive oxygen species (ROS). -The presence of metal ions (such as iron or copper) in the environment can catalyze reactions where antioxidants, including lycopene, contribute to oxidative processes. These metals can interact with lycopene, potentially leading to the formation of radicals. The mevalonate pathway produces cholesterol and a variety of isoprenoids, which are important for maintaining cell membrane integrity, protein prenylation, and other essential cellular functions. -One of the primary enzymes in this pathway is HMG-CoA reductase (3-hydroxy-3-methylglutaryl-coenzyme A reductase), which is the target of statin drugs used for lowering cholesterol. Some studies suggest that lycopene might downregulate the activity of HMG-CoA reductase or other enzymes in the mevalonate pathway. By doing so, lycopene could potentially reduce the synthesis of cholesterol and isoprenoids that are necessary for rapid cell proliferation—an especially relevant aspect in cancer cells. Lycopene typically used in a 100mg/day range for cancer (inhibition of the the Melavonate Pathway) -also has antiplatelet aggregation capability. -Note half-life 16–20 days. BioAv Heat processing, especially when combined with a small amount of fat, significantly enhances lycopene’s bioaccessibility and absorption. (20% under optimal conditions) Pathways: - ROS usually goes down, but may go up or down depending on dose and environment - Raises AntiOxidant defense in Normal Cells: ROS↓">ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑, - lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓ - inhibit Growth/Metastases : EMT↓, MMPs↓, MMP9↓, IGF-1↓, uPA↓, VEGF↓, ROCK1↓, FAK↓, RhoA↓, NF-κB↓, ERK↓ - reactivate genes thereby inhibiting cancer cell growth : EZH2↓, P53↑, Sp proteins↓, - cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, - inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓, - inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Integrins↓, - Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, ERK↓, JNK, - SREBP (related to cholesterol). - Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective, - Selectivity: Cancer Cells vs Normal Cells |
Source: HalifaxProj (inhibit) |
Type: |
Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer. ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations. However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS. "Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways." "During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity." "ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−". "Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules." Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea. Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells." Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers. -It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis. Note: Products that may raise ROS can be found using this database, by: Filtering on the target of ROS, and selecting the Effect Direction of ↑ Targets to raise ROS (to kill cancer cells): • NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS. -Targeting NOX enzymes can increase ROS levels and induce cancer cell death. -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS • Mitochondrial complex I: Inhibiting can increase ROS production • P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes) • Nrf2: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels • Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels • Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels • SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels • PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels • HIF-1α: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS • Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production. -Inhibiting fatty acid oxidation can increase ROS levels • ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels • Autophagy: process by which cells recycle damaged organelles and proteins. -Inhibiting autophagy can increase ROS levels and induce cancer cell death. • KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes. -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death. • DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels • PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels • SIRT1:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels • AMPK: regulates energy metabolism and can increase ROS levels when activated. • mTOR: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels • HSP90: regulates protein folding and can increase ROS levels when inhibited. • Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels • Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS. -Increasing lipid peroxidation can increase ROS levels • Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation. -Increasing ferroptosis can increase ROS levels • Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability. -Opening the mPTP can increase ROS levels • BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited. • Caspase-independent cell death: a form of cell death that is regulated by ROS. -Increasing caspase-independent cell death can increase ROS levels • DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS • Epigenetic regulation: process by which gene expression is regulated. -Increasing epigenetic regulation can increase ROS levels -PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS) ProOxidant Strategy:(inhibit the Melavonate Pathway (likely will also inhibit GPx) -HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more -Atorvastatin typically 40-80mg/day -Dipyridamole typically 200mg 2x/day -Lycopene typically 100mg/day range Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy |
1566- | betaCar,  | Lyco,  |   | Antioxidant and pro-oxidant effects of lycopene in comparison with beta-carotene on oxidant-induced damage in Hs68 cells |
- | in-vitro, | Nor, | HS68 |
1013- | Lyco,  |   | Lycopene induces apoptosis by inhibiting nuclear translocation of β-catenin in gastric cancer cells |
- | in-vitro, | GC, | AGS |
3268- | Lyco,  |   | Lycopene as a Natural Antioxidant Used to Prevent Human Health Disorders |
- | Review, | AD, | NA |
3275- | Lyco,  |   | Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer |
- | Review, | Var, | NA |
3277- | Lyco,  |   | Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent |
- | Review, | Var, | NA |
3528- | Lyco,  |   | The Importance of Antioxidant Activity for the Health-Promoting Effect of Lycopene |
- | Review, | Nor, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
3529- | Lyco,  |   | The antioxidant and anti-inflammatory properties of lycopene in mice lungs exposed to cigarette smoke |
- | in-vivo, | Nor, | NA |
3530- | Lyco,  |   | Lycopene Scavenges Cellular ROS, Modulates Autophagy and Improves Survival through 7SK snRNA Interaction in Smooth Muscle Cells |
- | in-vitro, | Stroke, | NA |
3531- | Lyco,  |   | Lycopene attenuates the inflammation and apoptosis in aristolochic acid nephropathy by targeting the Nrf2 antioxidant system |
- | in-vivo, | Nor, | NA |
3532- | Lyco,  |   | Lycopene alleviates oxidative stress via the PI3K/Akt/Nrf2pathway in a cell model of Alzheimer’s disease |
- | in-vitro, | AD, | NA |
3533- | Lyco,  | Chemo,  |   | Lycopene and chemotherapy toxicity |
- | Review, | Var, | NA |
3264- | Lyco,  |   | Pharmacological potentials of lycopene against aging and aging‐related disorders: A review |
- | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
1710- | Lyco,  |   | Lycopene: A Natural Arsenal in the War against Oxidative Stress and Cardiovascular Diseases |
- | Review, | CardioV, | NA |
1711- | Lyco,  |   | Nutritional Importance of Carotenoids and Their Effect on Liver Health: A Review |
- | Review, | Var, | NA |
1712- | Lyco,  |   | Lycopene Protects against Smoking-Induced Lung Cancer by Inducing Base Excision Repair |
- | in-vitro, | Lung, | A549 |
1713- | Lyco,  |   | Lycopene: A Potent Antioxidant with Multiple Health Benefits |
- | Review, | Nor, | NA |
1715- | Lyco,  |   | Pro-oxidant Actions of Carotenoids in Triggering Apoptosis of Cancer Cells: A Review of Emerging Evidence |
- | Review, | Var, | NA |
1716- | Lyco,  |   | Anti-inflammatory Activity of β-Carotene, Lycopene and Tri-n-butylborane, a Scavenger of Reactive Oxygen Species |
- | in-vitro, | AML, | RAW264.7 |
1717- | Lyco,  |   | Potential Role of Carotenoids as Antioxidants in Human Health and Disease |
- | Review, | Var, | NA |
1718- | Lyco,  |   | The role of carotenoids in the prevention of human pathologies |
- | Review, | Var, | NA |
1719- | Lyco,  |   | Lycopene for the prevention and treatment of prostate disease. |
- | Review, | Var, | NA |
1720- | Lyco,  |   | Antioxidant and Pro-oxidant Activities of Carotenoids |
- | Review, | Nor, | NA |
- | in-vitro, | Pca, | PC3 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Liver, | HepG2 |
3260- | Lyco,  |   | Lycopene in human health |
- | Review, | NA, | NA |
3261- | Lyco,  |   | Lycopene and Vascular Health |
- | Review, | Stroke, | NA |
3262- | Lyco,  |   | Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1 |
- | in-vitro, | adrenal, | SK-HEP-1 |
3534- | QC,  | Lyco,  |   | Synergistic protection of quercetin and lycopene against oxidative stress via SIRT1-Nox4-ROS axis in HUVEC cells |
- | in-vitro, | Nor, | HUVECs |
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:119 Target#:275 State#:% Dir#:%
wNotes=on sortOrder:rid,rpid